NASDAQ:OTIC - Otonomy Stock Price, Forecast & News

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy Inc (NASDAQ:OTIC) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. The biopharmaceutical company earned $0.13 million during the quarter, compared to analysts' expectations of $0.31 million. Otonomy had a negative net margin of 6,516.78% and a negative return on equity of 72.06%. View Otonomy's Earnings History.

Otonomy is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Otonomy.

4 brokers have issued 1-year price targets for Otonomy's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Otonomy's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 96.6% from the stock's current price. View Analyst Price Targets for Otonomy.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

News headlines about OTIC stock have trended extremely negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Otonomy earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Otonomy.

Otonomy saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 183,800 shares, an increase of 37.2% from the January 15th total of 134,000 shares. Based on an average daily trading volume, of 160,600 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the company's shares are sold short. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include ProQR Therapeutics (PRQR), Morphic (MORF), Xenon Pharmaceuticals (XENE), Mallinckrodt (MNK), Dynavax Technologies (DVAX), Mirum Pharmaceuticals (MIRM), DURECT (DRRX), Avid Bioservices (CDMO), Avedro (AVDR), Fulcrum Therapeutics (FULC), Urovant Sciences (UROV), Calithera Biosciences (CALA), Galera Therapeutics (GRTX), Recro Pharma (REPH) and Rigel Pharmaceuticals (RIGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Corbus Pharmaceuticals (CRBP), Catabasis Pharmaceuticals (CATB), Melinta Therapeutics (MLNT), Novavax (NVAX), Intercept Pharmaceuticals (ICPT), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), ACADIA Pharmaceuticals (ACAD), Strongbridge Biopharma (SBBP) and Spectrum Pharmaceuticals (SPPI).

Otonomy's stock is owned by many different of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.31%), Sofinnova Investments Inc. (4.93%), Ikarian Capital LLC (3.47%), Mercer Global Advisors Inc. ADV (0.45%), Bank of America Corp DE (0.44%) and Jacobs Levy Equity Management Inc. (0.22%). View Institutional Ownership Trends for Otonomy.

OTIC stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc. and Bank of America Corp DE. View Insider Buying and Selling for Otonomy.

OTIC stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Renaissance Technologies LLC, Mercer Global Advisors Inc. ADV and Sofinnova Investments Inc.. View Insider Buying and Selling for Otonomy.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $3.56.

Otonomy has a market capitalization of $109.47 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.

The official website for Otonomy is http://www.otonomy.com/.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]